In another phase Ib clinical trial (NCT03164772), an mRNA‐based vaccine BI1361849 (CV9202), incorporating cancer antigens such as NY‐ESO‐1 and complexed with the cationic protein protamine for self‐adjuvating, was investigated alongside local radiation therapy in 26 stage IV non‐small cell lung cancer (NSCLC) patients. Here, CTAG1B is linked to non-small cell lung carcinoma.